LSW Event

For over a century, immunologists have envisioned using Antibody Drug Conjugates (ADCs) to precisely target cancer cells with cell-killing payloads. However, it wasn’t until 2000 that the first ADC received FDA approval with limited success. Now most recently, multiple ADCs have gained additional approvals and are finally showing blockbuster potential. Interest is high with Pfizer […]